Search This Blog

Wednesday, January 31, 2024

FDA approves Boston Scientific's device for heart condition

   Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The FARAPULSE PFA System is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e., intermittent) atrial fibrillation (AF) and is a unique new alternative to standard-of-care thermal ablation treatment.

https://www.prnewswire.com/news-releases/boston-scientific-receives-fda-approval-for-farapulse-pulsed-field-ablation-system-302048807.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.